OKYO Pharma Limited (OKYO)
Market Cap | 40.22M |
Revenue (ttm) | n/a |
Net Income (ttm) | -13.27M |
Shares Out | 33.24M |
EPS (ttm) | -0.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,021 |
Open | 1.220 |
Previous Close | 1.240 |
Day's Range | 1.190 - 1.220 |
52-Week Range | 0.920 - 3.070 |
Beta | -3.26 |
Analysts | Strong Buy |
Price Target | 7.00 (+478.51%) |
Earnings Date | Aug 13, 2024 |
About OKYO
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, th... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for OKYO stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
![](https://cdn.snapi.dev/images/v1/k/l/press9-2399256.jpg)
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...
![](https://cdn.snapi.dev/images/v1/a/x/press5-2362137.jpg)
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...
![](https://cdn.snapi.dev/images/v1/r/l/press17-2351547.jpg)
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...
![](https://cdn.snapi.dev/images/v1/x/h/press13-2337083.jpg)
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
![](https://cdn.snapi.dev/images/v1/k/k/press14-2334813.jpg)
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
- Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDA...
![](https://cdn.snapi.dev/images/v1/x/g/press5-2332644.jpg)
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...
![](https://cdn.snapi.dev/images/v1/c/w/press18-2269020.jpg)
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam...
![](https://cdn.snapi.dev/images/v1/d/r/conf3-2218214.jpg)
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory ...
![](https://cdn.snapi.dev/images/v1/y/b/press19-2094702.jpg)
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory ...
![](https://cdn.snapi.dev/images/v1/h/j/press18-2064993.jpg)
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...
![](https://cdn.snapi.dev/images/v1/k/m/press3-2063566.jpg)
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...
![](https://cdn.snapi.dev/images/v1/4/7/press2-2063445.jpg)
OKYO Pharma Limited Announces Withdrawal of Public Offering
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...
![](https://cdn.snapi.dev/images/v1/c/r/press16-2062402.jpg)
OKYO Pharma Announces Public Offering of Ordinary Shares
LONDON and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...
![](https://cdn.snapi.dev/images/v1/x/j/press3-2055118.jpg)
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
LONDON and NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory...
![](https://cdn.snapi.dev/images/v1/j/v/press3-2042625.jpg)
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
LONDON and NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat DED to address the si...
![](https://cdn.snapi.dev/images/v1/5/a/press16-2023508.jpg)
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED...
![](https://cdn.snapi.dev/images/v1/p/t/press6-1995489.jpg)
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to t...
![](https://cdn.snapi.dev/images/v1/t/n/press10-1995461.jpg)
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry ey...
![](https://cdn.snapi.dev/images/v1/e/g/press1-1994200.jpg)
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED...
![](https://cdn.snapi.dev/images/v1/y/t/press15-1992411.jpg)
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED)...
![](https://cdn.snapi.dev/images/v1/u/9/press10-1922845.jpg)
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
LONDON and NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED)...
![](https://cdn.snapi.dev/images/v1/6/c/press5-1879300.jpg)
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
BALTIMORE, MD / ACCESSWIRE / May 9, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new rese...
![](https://cdn.snapi.dev/images/v1/e/c/press2-1867554.jpg)
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...
![](https://cdn.snapi.dev/images/v1/9/a/press7-1864658.jpg)
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
LONDON and NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye dis...
![](https://cdn.snapi.dev/images/v1/u/z/press10-1851373.jpg)
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 t...